Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Holding GKOS?
Track your performance easily
GKOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$59.22 - $145.84
Previous Close$140.83
Volume241.85K
Average Volume (3M)524.03K
Market Cap
$7.77B
Enterprise Value$7.66B
Total Cash (Recent Filing)$262.47M
Total Debt (Recent Filing)$157.13M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 19, 2025EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding55,137,429
10 Day Avg. Volume443,844
30 Day Avg. Volume524,027
Standard Deviation0.14
R-Squared0.15
Alpha0.00992
Financial Highlights & Ratios
Price to Book (P/B)11.67
Price to Sales (P/S)22.07
Price to Cash Flow (P/CF)-207.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.26
Enterprise Value/Gross Profit32.03
Enterprise Value/Ebitda-83.44
Forecast
1Y Price Target
$142.38Price Target Upside1.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Glaukos News
PremiumCompany Announcements
Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval
PremiumCompany Announcements
Glaukos Corp. Reports Record Third-Quarter Sales GrowthBulls Say, Bears Say
Bulls Say
Market PotentialA survey of 44 US ophthalmologists indicates healthy iDose uptake, with 86% expecting to implant iDose and procedures expected to increase significantly, supporting the analyst's above-consensus estimates.
Product PerformanceIDose sales doubled in the third quarter to approximately $8.8M, surpassing buyside expectations.
Revenue And GrowthGlaukos Corp reported 3Q24 revenue of $96.7M, which was well ahead of analyst and consensus estimates.
Bears Say
Financial PerformanceDespite the stronger than expected 3Q iDose showing, full-year guidance was only raised by $5 million at the midpoint versus the $4 million 3Q beat.
Market CompetitionSoftness in the base glaucoma business has been noted, attributed to LCD headwinds for MIGS and increased competition in overseas markets.
Operational ChallengesGKOS is waiting to collect iDose payments, with a collection window that was extended out to 90-180 days.
---
Ownership Overview
5.91% Insiders
40.07% Mutual Funds
25.77% Other Institutional Investors
3.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $59.22 and its highest was $145.84 in the past 12 months.
What is Glaukos’s market cap?
Currently, no data Available
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Feb 19, 2025 which is in 89 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Nov 04, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.478 by $0.198.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -$0.38.
How many shares outstanding does Glaukos have?
Glaukos has 55,137,430 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.478. Following the earnings report the stock price went down -2.679%.
Which hedge fund is a major shareholder of Glaukos?
Among the largest hedge funds holding Glaukos’s share is PRIMECAP Management Co. It holds Glaukos’s shares valued at 162M.
---
Glaukos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.38 (1.10% Upside)
$142.38 (1.10% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 185.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $392.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 19.2%
Last 30 Days ▲ 19.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
124.07%
12-Months-Change
Fundamentals
Return on Equity
-26.10%
Trailing 12-Months
Asset Growth
-2.33%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
---
GKOS Earnings Call
Q3 2024
0:00 / 0:00
---
GKOS Stock 12 Month Forecast
Average Price Target
$142.38
▲(1.10% Upside)
Technical Analysis
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+67.48%
assigned a buy rating 18 days ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +67.48% per trade.
---